AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27788026
Drug: Amitriptyline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (1 mg/kg/day)
Trial: 27788026
Drug: Topiramate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (2 mg/kg/day)
Trial: 23238577
Drug: STOP-Bang score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOP-Bang score ≥ 3 with serum HCO₃⁻ level ≥ 28 mmol/L
Trial: 20704458
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium fast-disintegrating tablets (FDTs) 50 mg
Trial: 20704458
Drug: Commercial tablets
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablets of diclofenac potassium 50 mg
Trial: 17011374
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil (phase 1)
Trial: 17011374
Drug: Dose optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose optimization and customized instructions (phase 2)
Trial: 15001726
Drug: Interpersonal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal group therapy
Trial: 9580524
Drug: Prednisone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 0.5 mg/kg/day
Trial: 19099126
Drug: Prednisone 1
RxNorm normalized name: prednisone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1 mg/kg/day
Trial: 31652094
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg orally on days 1 to 21 of a 28-day cycle)
Trial: 24325111
Drug: Task-oriented approach
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented approach in combination with articulation approach
Trial: 22136481
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg vitamin B12 and 400 μg folic acid daily (with 15 μg (600 IU) vitamin D included)
Trial: 22136481
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (with 15 μg (600 IU) vitamin D included)
Trial: 12755456
Drug: Venlafaxine (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (225 mg daily)
Trial: 12755456
Drug: Cocaine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0, 12, 25, or 50 mg)
Trial: 2037706
Drug: AICA-riboside (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AICA-riboside (10, 25, 50, and 100 mg/kg doses)
Trial: 2037706
Drug: AICA-riboside (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AICA-riboside (IV and oral administration)
Trial: 2037706
Drug: AICA-riboside (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AICA-riboside (IV administration)
Trial: 2037706
Drug: AICA-riboside (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AICA-riboside (oral administration)
Trial: 21462215
Drug: Q‐ter 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q‐ter 320 mg + creatine 340 mg
Trial: 16931611
Drug: Parenteral carnitine
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral carnitine supplementation (20 mg/kg/d) at week 1 (n = 6)
Trial: 16931611
Drug: Enteral carnitine
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral carnitine supplementation (20 mg/kg/d) at week 8 (n = 8)
Trial: 16931611
Drug: Paired analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired analysis of parenteral at week 1 and enteral at week 8 (n = 5)
Trial: 15302144
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (compensatory training, emphasizing enhancement of visual and somatosensory function, and balance training) administered three times weekly for 12 weeks.
Trial: 15302144
Drug: Placebo intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention (language development activities) administered three times weekly for 12 weeks.
Trial: 11403983
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/day PO
Trial: 11403983
Drug: Haloperidol 10
RxNorm normalized name: haloperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 10 mg/day PO
Trial: 8087820
Drug: Nitrates (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (intravenous, oral, or transdermal)
Trial: 8087820
Drug: Nitrates (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (combined with lisinopril)
Trial: 2832598
Drug: Continuous progestin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous progestin (2.5 mg daily)
Trial: 2832598
Drug: Cyclic progestin
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic progestin (5 mg daily or 5 mg during the last 12 days of a 28-day cycle)
Trial: 24398576
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy (frequency of 50 Hz, amplitude of 2 mm, four 1-min series with 1-min rest intervals in three body positions)
Trial: 23740686
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 500 µg daily for 8 weeks
Trial: 20646353
Drug: bLf 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bLf 100 mg/twice/day
Trial: 20646353
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 520 mg/day
Trial: 8469455
Drug: Sequential vacuum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential vacuum and forceps-assisted delivery
Trial: 8469455
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of vacuum and forceps for assisted delivery
Trial: 3780285
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of propranolol
Trial: 27196818
Drug: Post-MRI ICD
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-MRI ICD sensing and treatment of ventricular tachyarrhythmias (VT/VF)
Trial: 18426146
Drug: High-dose sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sublingual immunotherapy (SLIT) with a 6-grass pollen mixture, once daily for 2 years
Trial: 16643482
Drug: Tolterodine extended-release
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine extended-release (ER) 4 mg once daily
Trial: 10984368
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 microg once daily
Trial: 10984368
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 200 microg twice daily
Trial: 1453146
Drug: Clarithromycin, 250
RxNorm normalized name: Clarithromycin, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 250 mg twice daily
Trial: 1453146
Drug: Penicillin VK,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin VK, 250 mg three times daily
Trial: 6660217
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg guava juice (acute i.p. treatment)
Trial: 6660217
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of guava juice
Trial: 6660217
Drug: Chlorpropamide and
RxNorm normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpropamide and metformin (control)
Trial: 31536556
Drug: Everolimus (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (5-10 ng/mL) with mycophenolic acid (MPA) and basiliximab
Trial: 29914943
Drug: Fluconazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (800 mg q24h) in combination with amphotericin B deoxycholate (1 mg/kg q24h)
Trial: 29914943
Drug: Fluconazole (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (1,200 mg q24h)
Trial: 29914943
Drug: Fluconazole monotherapy
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole monotherapy (from meta-analysis)
Trial: 18307772
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g FFA PinnoThin
Trial: 15756254
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of outpatient subcutaneous interleukin‐2 (sc‐rIL‐2), subcutaneous interferon‐alpha2a (sc‐rIFN‐alpha2a), and intravenous 5‐fluorouracil (iv‐5‐FU) according to the standard Atzpodien regimen
Trial: 10065646
Drug: Simultaneous placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous placement of titanium implants
Trial: 10065646
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of titanium implants
Trial: 1699272
Drug: Iloprost (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (2 ng/kg/min, intravenously for 6 hours daily for 28 days)
Trial: 19935461
Drug: Angiotensin‐II‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐II‐converting enzyme inhibitors or angiotensin II receptor blockers
Trial: 12742466
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d sirolimus
Trial: 12742466
Drug: 2 mg/d
RxNorm normalized name: Uceris, 2 mg/dose rectal foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/d sirolimus
Trial: 9113932
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential therapy
Trial: 8239913
Drug: Tołpa Torf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tołpa Torf Preparation (TTP) administered orally, 5 mg daily for three weeks
Trial: 8239913
Drug: Tołpa Torf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tołpa Torf Preparation (TTP)
Trial: 3104124
Drug: TTS NTG
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS NTG 40 cm2 (releasing 20 mg of NTG over 24 hours)
Trial: 3104124
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg SR
Trial: 3104124
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg SR
Trial: 26205903
Drug: Protocol modifications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol modifications allowing for inclusion of patients receiving aspirin
Trial: 18332071
Drug: TPA-based antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA-based antibiotic lock (ABL)
Trial: 18332071
Drug: Heparin-based antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-based antibiotic lock (ABL)
Trial: 6160353
Drug: N-allyl-clonidine (ST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-allyl-clonidine (ST 567) 40 mg, i.v.
Trial: 31374027
Drug: GnRH pulse
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH pulse therapy
Trial: 31374027
Drug: HCG/HMG combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG/HMG combined treatment
Trial: 23113645
Drug: SST using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST using Ologen implant
Trial: 19027977
Drug: Miglitol 150
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 150 mg/day
Trial: 19027977
Drug: Mitiglinide 30
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 30 mg/day
Trial: 16269646
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIIa (rFVIIa) administered intravenously within 4 hours of ICH onset
Trial: 11975864
Drug: Cimicifugae racemosae
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifugae racemosae rhizoma (40 mg/day)
Trial: 11975864
Drug: Cimicifugae racemosae
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifugae racemosae rhizoma (39 mg)
Trial: 11975864
Drug: Cimicifugae racemosae
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifugae racemosae rhizoma (127.3 mg)
Trial: 11975864
Drug: Cimicifugae racemosae
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifugae racemosae rhizoma (higher dose)
Trial: 11975864
Drug: Cimicifugae racemosae
RxNorm normalized name: Cimicifuga racemosa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifugae racemosae rhizoma (all doses)
Trial: 7852113
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose total body irradiation (STBI)
Trial: 7346530
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Slo-Phyllin Gyrocap
Trial: 7346530
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Theo-dur tablet
Trial: 31287046
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) of praziquantel, given annually or twice over 4 years
Trial: 19333160
Drug: Opioid (oxycodone)
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid (oxycodone)
Trial: 2673621
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day viqualine
Trial: 2673621
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day viqualine
Trial: 2673621
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of viqualine
Trial: 10942
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 or 2 mg)
Trial: 28046034
Drug: Daily notifications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily notifications within pre-defined time frames
Trial: 22105724
Drug: Deep sedation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation with intravenous propofol administered by anesthesiologist
Trial: 16227143
Drug: Diclofenac after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac after pre-treatment with bendroflumethiazide and enalapril
Trial: 9813556
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (5‐20 ng/kg/min)
Trial: 9813556
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (0.7‐2.8 micrograms/kg/min)
Trial: 16025317
Drug: lormetazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lormetazepam (1 mg)
Trial: 21966064
Drug: zopiclone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zopiclone (7.5 mg)
Trial: 28002035
Drug: Omega-3 supplement
RxNorm normalized name: Systane Vitamin Omega-3 Supplement Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplement for 12 weeks
Trial: 28002035
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no omega-3 supplement)
Trial: 23297557
Drug: Zhizhukuanzhong capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhizhukuanzhong capsules (ZZKZC)
Trial: 23297557
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Electroacupuncture + ZZKZC)
Trial: 23297557
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 mg mosapride three times daily and 20 mg pantoprazole twice daily)
Trial: 18538974
Drug: New transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New transdermal fentanyl patch
Trial: 18538974
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid treatment
Trial: 11738537
Drug: haloperidol 12
RxNorm normalized name: haloperidol 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol 12 mg/day
Trial: 7876509
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (control)
Trial: 2690165
Drug: Nefazodone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone therapy
Trial: 24167166
Drug: Nonmedical prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmedical prescription opiate use (NPOU)
Trial: 24167166
Drug: Nonmedical prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmedical prescription sedative use (NPSU)
Trial: 24167166
Drug: Current home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current home prescription for opioids
Trial: 24167166
Drug: Current home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current home prescription for sedatives
Trial: 24167166
Drug: Receiving an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receiving an intravenous opioid in the ED
Trial: 16943538
Drug: Reduced-dose craniospinal
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with lomustine (CCNU), cisplatin, and vincristine
Trial: 16943538
Drug: Reduced-dose craniospinal
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with cyclophosphamide, cisplatin, and vincristine
Trial: 25908603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as standard treatment)
Trial: 1286488
Drug: Manidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine (10 to 40 mg daily for 12 months)
Trial: 1286488
Drug: Delapril (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril (15 to 60 mg daily for 12 months)
Trial: 2408842
Drug: Propafenone 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 450 mg/d
Trial: 2408842
Drug: Disopyramide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 600 mg/d
Trial: 2408842
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg/d
Trial: 29873953
Drug: Adjunctive brexpiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brexpiprazole 2 mg/d
Trial: 21134044
Drug: onabotulinumtoxinA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onabotulinumtoxinA plus 24‐mg/mL cohesive gel
Trial: 21070457
Drug: 24‐mg/mL cohesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24‐mg/mL cohesive gel alone
Trial: 12368933
Drug: Lisinopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (ACE inhibitor) for three days
Trial: 382750
Drug: sulpiride (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulpiride (up to 1,800 mg per day)
Trial: 382750
Drug: chlorpromazine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorpromazine (up to 675 mg)
Trial: 29508498
Drug: Locator-retained mandibular
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locator-retained mandibular overdentures with implants in the premolar areas (PM group)
Trial: 29508498
Drug: Locator-retained mandibular
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locator-retained mandibular overdentures with implants in the canine regions (CA group)
Trial: 23883812
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied three times daily for 30 days
Trial: 21836471
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon α‐2b (1.5 μg/kg/wk) plus fixed ribavirin dose (800 mg/d) or weight‐based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks
Trial: 16458458
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact once daily for 4 weeks
Trial: 15548461
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment subgroups